Pages that link to "Template:ReferenceData"

The following pages link to Template:ReferenceData:

Displaying 50 items.

• Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 5.6.6.1 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 9.2.2 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.14-002 (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 3.3 c) (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 76 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 69 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 65 (transclusion) (← links)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 40a Absatz 3 (transclusion) (← links)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 26 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 2 16. (transclusion) (← links)
• Reference:GBR Directive 2001/20/EC 04-Apr-2001 Article 3 (transclusion) (← links)
• Reference:GBR Directive 93/42/EEC 11-Oct-2007 Annex VIII 1. ; 2. ; 2.2 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.6 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.17.1 (transclusion) (← links)
• Reference:ICH ICH E9 Guideline 1998 4.5 (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.15 (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 5.14 (transclusion) (← links)
• Reference:WMA Declaration of Helsinki 2024 34 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 8.2 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 2 Paragraph 26 - 29 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 37 Paragraph 1 – 7 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 38 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 76 Paragraph 3 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 77 Paragraph 1 – 3 (transclusion) (← links)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 77 Paragraph 5 (transclusion) (← links)
• Reference:FRA AEC DOC012 v03 Avis aux promoteurs d’investigations cliniques de DM (RIPH1) – Partie II 16-May-2025 2.-002 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1. (p) (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 27 (transclusion) (← links)
• Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 5 (5) (transclusion) (← links)
• Reference:GBR Directive 2001/20/EC 04-Apr-2001 Article 10 (c) (transclusion) (← links)
• Reference:GBR The Medical Devices Regulations 2002 11-Feb-2021 Article 16 (11) (transclusion) (← links)
• Reference:GBR Directive 93/42/EEC 11-Oct-2007 Article 15 6. - 7.-002 (transclusion) (← links)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.113-002 (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.113 (transclusion) (← links)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.123 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.38 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.42 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.44 (transclusion) (← links)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.45 (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.3 (q) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.46 (b) - (c)-002 (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (a) (2) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (1) - (3) (transclusion) (← links)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.150 (b) (7)-001 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.11.4.5.2 (transclusion) (← links)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 8.3 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix C 2 (transclusion) (← links)
• Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 14.3 (transclusion) (← links)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 8.3 (transclusion) (← links)
• Reference:EU Regulation (EU) 536/2014 - clinical trials 05-Dec-2022 Article 58 (transclusion) (← links)